Medicines Australia Appoints Interim CEO
This article was originally published in Scrip
Executive Summary
Australia's pharmaceutical industry association, Medicines Australia, has appointed Lee Hill as its new interim CEO after its former CEO, Tim James, resigned in December. Mr Hill, who will likely stay in the position until June, has more than 10 years' experience as a "senior business leader," says the association. He has held posts such as CEO or managing director at leading pharmaceutical companies and consultancies. During the next six months he will prepare for a smooth transition for his successor and will work with the association's board to identify the organization's needs for ensuring "long-term success".
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.